On December 13th, three months after submitting the listing application to the Hong Kong Stock Exchange, WuXi PharmaTech was officially listed on the Hong Kong Main Board today. The WuXi PharmaTech public offering raised up to HK$8.33 billion and issued a total of 116 million H shares, 90% of which were for international offerings and 10% for public offerings at HK$68 per share. It opened at HK$67 today, down 1.47%. On October 30, 2012, Fosun Pharma went to the Hong Kong Stock Exchange and became the second A+H listed pharmaceutical company in the Mainland after Shanghai Pharmaceuticals. Under the eyes of the market, WuXi PharmaTech, which is known by the industry as “the pharmaceutical industry Huaweiâ€, is about to become the third pharmaceutical company to build a “A+H†share financing platform. According to the prospectus, WuXi PharmaTech’s proceeds from the listing in Hong Kong will be used to: expand the production capacity of global business units; acquire CRO and CMO/CDMO companies; invest in and cultivate companies with innovative business models and growth potential in the healthcare industry; High-end technologies, such as drug development platforms and automated laboratories using artificial intelligence, medical health data platforms, and mechanochemical technologies. According to the information, WuXi PharmaTech is an open, all-round and integrated service platform for international pharmaceutical research and development. The main focus is on reshaping the business of discovering, developing and manufacturing innovative drugs. Provide comprehensive research and production services to cover the discovery, development and production of small molecule drugs. It also provides research and development and production services for cell and gene therapy, as well as medical device testing services. In addition, WuXi PharmaTech is actively expanding its business line this year, including expanding the proportion of investment business and continuing to promote globalization. According to the prospectus, the company has 26 R&D bases/branch offices around the world serving more than 3,000 customers. Established in 2000, WuXi PharmaTech was listed on the New York Stock Exchange in August 2007. In April 2015, WuXi PharmaTech CEO Li Ge and Huiqiao Capital Group jointly proposed a privatization offer. The fate of the HKEx is that since the privatization of its subsidiary, Yaomingkang, WuXi PharmaTech has started the spin-off strategy. The company's Hefei Pharmaceutical and Yaoming Biotech entered the New Third Board and Hong Kong stock market in April 2015 and June 2017 respectively. The unicorn, which is active on the exchange, has been delisted from the NYSE for only three years, less than four months before the last landing in the secondary market. Judging from its performance in recent years, WuXi PharmaTech has a full confidence. For the years ended December 31, 2015, 2016 and 2017, WuXi PharmaTech’s revenues were 4.883 billion yuan, 6.116 billion yuan and 7.765 billion yuan respectively, and the net profit for the same period was 684 million. Yuan, 1.121 billion yuan and 12.97 yuan. According to its 2018 semi-annual report, the company's revenue during the reporting period was 4.409 billion, an increase of 20.29% year-on-year. The net profit attributable to shareholders of listed companies was 1.272 billion yuan, a year-on-year increase of 71.31%. According to the prospectus, WuXi PharmaTech's revenue mainly comes from laboratory services in China, laboratory services in the US, clinical research and other CRO services, and CMO/CDMO services. Among them, in terms of performance in the first half of 2018, WuXi PharmaTech’s top four businesses received revenues of 2.416 billion yuan, 546 million yuan, 231 million yuan and 1.209 billion yuan respectively. District laboratory service business revenue decreased slightly year-on-year. From a regional perspective, US customers accounted for 52.9% of revenue, much higher than Europe, China and other parts of Asia. The incident of entering the A-share market in May this year has also affected the influence of WuXi PharmaTech. The IPO prospectus submitted to Hong Kong mentioned that the company's current ratio increased from 1.18 on December 31, 2017 to 1.58 on June 30, 2018, due to the proceeds from the A-share listing. The net gearing ratio fell from 0.24 to 0.17 during the reporting period from the end of 2017 to 2018. In addition, during the application for the Hong Kong stock IPO by WuXi PharmaTech, the third quarter report for 2018 was also released. According to the report, as of the end of the reporting period, WuXi PharmaTech had a total of 17,461 employees, including 13,853 R&D personnel and 6,599 graduates with a master's degree or higher. During the reporting period, WuXi PharmaTech's operating income was 2.512 billion yuan, an increase of 24.82% over the same period of the previous year; the net profit attributable to shareholders of listed companies was 656 million yuan, an increase of 104.77% over the same period of the previous year. Overall, each business segment still maintains a good development trend. Under the two institutional advantages of “different rights to the same stock†and “allowing qualified unprofitable biotech companies to listâ€, the Hong Kong Stock Exchange has ushered in the “flock†listing of big health companies this year. Apparently, WuXi PharmaTech and Gloria Biology, Hualing Medicine, Mengke Medicine, and Cinda Biology have become the first people to eat crabs after the introduction of the New Deal, and rely on the previous “entanglements†on multiple exchanges. Relatively beautiful performance, WuXi PharmaTech’s listing in Hong Kong was favored by industry professionals. The “A+H†stock model not only expands the financing channels of enterprises, but in the process of globalization, WuXi PharmaTech also does not retain the careful layout at the capital level. Greenhouse Plastic Plastic Clamps Greenhouse Plastic Plastic Clamps,Greenhouse Structure Connecting Clamps,Agricultural Greenhouses Clamps,Plastic Clamps JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.thgreenhouse.com